You are here

ESMO’s New Guidelines for Metastatic Colorectal Cancer

Eric Van Cutsem, MD, Chairperson of the ESMO Consensus Conference, discusses the new ESMO consensus guidelines for the management of metastatic colorectal cancer. Among other things, the detailed document discusses biomarker testing, emerging technologies, and the multidisciplinary, multimodal approaches used increasingly in treatment.

ESMO World Congress on Gastrointestinal Cancer, June 29–July 2, 2016

How a Texas ACO Corralled Diabetes

Jose F. Peña, MD, head of the Rio Grande Valley ACO, describes impressive results for the organization’s comprehensive program to improve diabetes care and lower related Medicare costs in one of the nation’s poorest areas.

American Diabetes Association 76th Scientific Sessions, June 2016

Promising Results for Three Intralesional Oncolytic Agents

Robert H. I. Andtbacka, MD, of the Huntsman Cancer Institute in Utah, reports on three oncolytic immunotherapy studies involving intralesional agents. The combinations of HF10 with ipilimumab and PV-10 with radiation showed promising results, while a study of responders and nonresponders to coxsackievirus A21 suggests avenues for future research.

American Society of Clinical Oncology, June 2016

Regorafenib Safe for Older Colorectal Cancer Patients

Eric Van Cutsem, MD, discusses a subgroup analysis involving patients 75 years of age and older in the Consign study of regorafenib for treatment-refractory metastatic colorectal cancer. The analysis found no major differences in safety compared with younger patients as long as the patients were fit enough to be eligible for treatment—so age itself is no reason to withhold regorafenib.

ESMO World Congress on Gastrointestinal Cancer, June 29–July 2, 2016

Venetoclax Very Effective Against CLL

Robert A. Hromas, MD, Chair of the Department of Internal Medicine at the University of Florida College of Medicine, describes “very exciting” findings about venetoclax in treating chronic lymphocytic leukemia (CLL). The drug was very effective among hard-to-treat patients with the 17p deletion, and he believes it may hold promise for a range of other CLL patients as well. 

American Society of Hematology, December 2015

Pages